Shaw, Founder and Executive Chairperson of Biocon, on catching up with China, the right recruitment policies, and more.

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

The proposed Metro 8 corridor will provide a critical link between the Chhatrapati Shivaji Maharaj International Airport in Mumbai and the Navi Mumbai International Airport MUMBAI: The state has ...

DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions ...

The biotech firm joins a group of health care companies advancing their IPO plans. Maze Theraupeutics Inc., which develops precision treatments for kidney, heart and metabolic diseases ...

The future of the Bay Area biotech firm Allakos was riding on one clinical trial, for a drug designed to treat the skin condition known as chronic spontaneous urticaria, or chronic hives.

Conclusion Vardhaan Lithium (I) Pvt. Ltd.'s initiative is a testament to India's ambition to lead the global energy revolution. By reducing dependency on imports, embracing cutting-edge technology, ...

Sam Altman, pictured at President Donald Trump's inauguration, is contributing to another round of funding for Retro Biosciences. © 2025 Fortune Media IP Limited ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics revealing plans to go public while Hong Kong-listed Ascentage Pharma joins ...

EU targets AI, biotech, green tech, advance materials sectors Draghi report said EU is falling behind US and China France, Trump push EU to cut business red tape EU plans include 25% reduction of ...

Ascentage Pharma, a China-based drug developer with global ambitions, now has $126.4 million from a U.S. IPO that will mainly support late-stage clinical development of two medicines that could ...

How will the Trump administration approach healthcare regulation? Will generalist investors remain wary of biotech? Can the industry’s expensive pivot into immunology and obesity deliver drugs ...